Institutional members access full text with Ovid®

Share this article on:

Efficacy of Infliximab in Intestinal Behçet’s Disease: A Korean Multicenter Retrospective Study

Lee, Jin Ha MD*; Cheon, Jae Hee MD, PhD*; Jeon, Seong Woo MD, PhD; Ye, Byong Duk MD, PhD; Yang, Suk-Kyun MD, PhD; Kim, Young-Ho MD, PhD§; Lee, Kang-Moon MD, PhD; Im, Jong Pil MD, PhD; Kim, Joo Sung MD, PhD; Lee, Chang Kyun MD, PhD**; Kim, Hyo Jong MD, PhD**; Kim, Eun Young MD, PhD††; Kim, Kyeong Ok MD, PhD‡‡; Jang, Byung Ik MD, PhD‡‡; Kim, Won Ho MD, PhD*

doi: 10.1097/MIB.0b013e31828f19c9
Original Clinical Articles

Background: Although infliximab is widely accepted as a therapeutic option for inflammatory bowel disease, its therapeutic efficacy for the treatment of intestinal Behçet’s disease (BD) is unknown. We investigated the short-term and long-term response rates to infliximab in intestinal BD and predictive factors of sustained treatment response following infliximab treatment.

Methods: This study was conducted using a retrospective noncontrolled review of medical records from 8 tertiary hospitals in Korea. We collected clinical, demographic, and laboratory data for patients with 28 patients with intestinal BD who received at least 1 dose of infliximab. Response rates of infliximab at 2, 4, 30, and 54 weeks for each patient and factors predictive of sustained response were investigated. Adverse events were also identified.

Results: The median duration of follow-up after initial infliximab infusion was of 29.5 months. The clinical response rates at 2, 4, 30, and 54 weeks were 75%, 64.3%, 50%, and 39.1%, respectively, with clinical remission rates of 32.1%, 28.6%, 46.2%, and 39.1%, respectively. After multivariate analysis, older age at diagnosis (≥40 yr), female sex, a longer disease duration (≥5 yr), concomitant immunomodulator use, and achievement of remission at week 4 were found to be predictive factors of sustained response. There was 1 serious infection but no malignancies or deaths in this study.

Conclusions: Infliximab was a well-tolerated and effective therapy for patients with moderate-to-severe intestinal BD. Moreover, we found 5 predictive factors associated with sustained response, which might assist in optimal patient selection for infliximab treatment.

Article first published online 22 May 2013

*Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea;

Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea;

Department of Gastroenterology, University of Ulsan College of Medicine, Seoul, Korea;

§Division of Gastroenterology, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea;

Department of Internal Medicine, The Catholic University College of Medicine, Seoul, Korea;

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea;

**Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea;

††Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea; and

‡‡Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.

Reprints: Jae Hee Cheon, MD, PhD, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea (e-mail: geniushee@yuhs.ac).

The authors have no conflicts of interest to disclose.

Received January 09, 2013

Accepted February 25, 2013

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website